What Is the Normal Dose of Topamax for Weight Loss? A Complete Dosing Protocol

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Topamax (topiramate) for weight loss typically starts at 25 mg daily and titrates to 100-200 mg daily over 4-8 weeks, though this is off-label use
• The FDA-approved weight-loss formulation is Qsymia (phentermine/topiramate ER), which contains 7.5-15 mg topiramate in the therapeutic dose
• Most prescribers use immediate-release topiramate 50-100 mg twice daily for weight loss, not the extended-release formulation
• Topiramate monotherapy produces 5-6% total body weight loss at 6 months in clinical trials, significantly less than GLP-1 receptor agonists

Direct answer (40-60 words)

The typical off-label dose of Topamax (topiramate) for weight loss starts at 25 mg once daily, increasing by 25-50 mg weekly to a target of 100-200 mg daily, split into two doses. The FDA has not approved topiramate alone for weight loss. Most weight loss occurs at doses of 96 mg or higher.

Table of contents

1. Why "normal dose" is the wrong question for off-label topiramate
2. The FDA-approved topiramate weight-loss dose (and why almost nobody uses it)
3. Standard off-label titration protocols prescribers actually follow
4. Dose-response data: how much weight loss at each dose level
5. What most articles get wrong about topiramate dosing
6. Immediate-release vs extended-release: which formulation for weight loss
7. The cognitive side effect threshold and why it matters for dosing
8. When prescribers stop at 100 mg vs push to 200 mg
9. Topiramate dosing compared to GLP-1 receptor agonists
10. The case against using topiramate for weight loss in 2026
11. Storage, missed doses, and discontinuation protocols
12. When to contact your provider about dose adjustments

Why "normal dose" is the wrong question for off-label topiramate

Topiramate has three different FDA-approved indications, each with different dosing:

• Epilepsy (monotherapy): 400 mg daily in divided doses
• Migraine prophylaxis: 100 mg daily in divided doses
• Weight management (as Qsymia only): 7.5 mg or 15 mg topiramate ER combined with phentermine

When physicians prescribe topiramate monotherapy for weight loss, they're using it off-label. There is no FDA-established "normal dose" for this indication. What exists instead is a collection of dosing protocols derived from clinical trials conducted between 2003 and 2014, most of which tested doses between 96 mg and 256 mg daily.

The dose that produces meaningful weight loss (defined as 5% or more total body weight) in clinical trials is 96 mg daily or higher. Below that threshold, weight loss is statistically significant but clinically modest, typically 2-3% of total body weight (Bray et al., Obesity Research 2003).

The practical dosing question is not "what's normal" but "what's the minimum effective dose that stays below the cognitive side effect threshold for this specific patient." That calculation varies by baseline weight, medication tolerance, kidney function, and whether the patient is on other carbonic anhydrase inhibitors.

The FDA-approved topiramate weight-loss dose (and why almost nobody uses it)

The only FDA-approved topiramate formulation for weight loss is Qsymia, a combination capsule containing phentermine and extended-release topiramate. The dosing is:

• Starting dose: phentermine 3.75 mg / topiramate ER 23 mg daily for 14 days
• Recommended dose: phentermine 7.5 mg / topiramate ER 46 mg daily
• Maximum dose: phentermine 15 mg / topiramate ER 92 mg daily

Notice the topiramate component: 46 mg in the standard therapeutic dose, 92 mg at the maximum. These are significantly lower than the 100-200 mg doses used in off-label topiramate monotherapy protocols.

Why the discrepancy? Qsymia's weight-loss effect comes primarily from phentermine, a sympathomimetic amine that suppresses appetite. The topiramate component is present at a dose high enough to contribute additional weight loss but low enough to minimize cognitive side effects. The combination produces approximately 10% total body weight loss at one year, compared to 5-6% for topiramate monotherapy at higher doses (Gadde et al., Lancet 2011).

Qsymia's market penetration remains limited. As of Q4 2025, fewer than 40,000 prescriptions per month are filled in the U.S., compared to over 1.2 million monthly prescriptions for semaglutide. The reasons include cost (typically $150-200 per month without insurance), the phentermine component's Schedule IV controlled substance status, and contraindications in patients with cardiovascular disease or hyperthyroidism.

Most physicians who want to prescribe topiramate for weight loss use generic immediate-release topiramate, not Qsymia. The dosing protocols for that approach come from the pre-Qsymia clinical trial literature.

Standard off-label titration protocols prescribers actually follow

The two most common titration schedules for off-label topiramate weight loss, derived from the EQUIP and SEQUEL trials (Wilding et al., International Journal of Obesity 2004):

Protocol 1: Conservative 8-week titration to 100 mg

Week	Morning dose	Evening dose	Total daily dose
1	25 mg	0 mg	25 mg
2	25 mg	25 mg	50 mg
3	25 mg	25 mg	50 mg
4	50 mg	25 mg	75 mg
5	50 mg	50 mg	100 mg
6-8	50 mg	50 mg	100 mg

Protocol 2: Aggressive 6-week titration to 200 mg

Week	Morning dose	Evening dose	Total daily dose
1	25 mg	0 mg	25 mg
2	25 mg	25 mg	50 mg
3	50 mg	50 mg	100 mg
4	75 mg	75 mg	150 mg
5	100 mg	100 mg	200 mg
6+	100 mg	100 mg	200 mg

The conservative protocol is more common in primary care settings. The aggressive protocol appears more often in bariatric medicine clinics where patients are monitored more frequently and cognitive side effects can be caught earlier.

A third approach, used by some prescribers, holds at 50 mg twice daily (100 mg total) for 4-8 weeks before deciding whether to increase. This "test dose plateau" lets the prescriber assess weight-loss response and side effect burden before committing to higher doses. If a patient loses 3-4% of body weight at 100 mg daily with minimal side effects, some prescribers stay there rather than pushing to 200 mg.

Dose-response data: how much weight loss at each dose level

The clearest dose-response data comes from a 2003 multicenter trial (Bray et al., Obesity Research) that randomized 1,289 patients to placebo, topiramate 64 mg, 96 mg, 128 mg, 192 mg, or 256 mg daily for 60 weeks. All patients received lifestyle counseling.

Weight loss at 60 weeks by dose:

Dose	Mean weight loss (% of baseline)	Patients achieving ≥5% loss	Patients achieving ≥10% loss
Placebo	2.6%	20%	7%
64 mg	4.8%	38%	16%
96 mg	5.0%	44%	19%
128 mg	4.4%	41%	15%
192 mg	6.3%	50%	23%
256 mg	6.3%	53%	24%

The data shows a dose-response relationship up to 192 mg, with no additional benefit at 256 mg. The 128 mg dose underperformed 96 mg in this trial, likely due to higher dropout rates from side effects.

A separate analysis (Wilding et al., International Journal of Obesity 2004) found that patients who reached 96 mg or higher and stayed on treatment for at least 16 weeks lost an average of 6.5% of baseline weight by 6 months. Patients who discontinued early or never exceeded 64 mg lost an average of 2.1%.

The practical takeaway: meaningful weight loss requires reaching at least 96-100 mg daily and staying there for a minimum of 12-16 weeks. Doses below 96 mg produce weight loss that's statistically significant in trials but often clinically disappointing in practice.

What most articles get wrong about topiramate dosing

The most common error in published content about topiramate for weight loss is conflating the Qsymia dose with the off-label monotherapy dose. Articles state "the typical dose is 46-92 mg" because that's what Qsymia contains, then fail to mention that Qsymia includes phentermine and that monotherapy protocols use 100-200 mg.

A patient reading "the dose is 46 mg" and then receiving a prescription for 100 mg twice daily reasonably assumes their prescriber made an error or is being aggressive. In fact, 200 mg daily is the median dose in published off-label protocols.

The second common error is stating that topiramate "should be titrated slowly to minimize side effects" without specifying what "slowly" means. A 25 mg per week increase is slow. A 50 mg per week increase is moderate. A 100 mg per week increase (going from 50 mg to 150 mg in one jump) is fast and associated with higher dropout rates. The published literature supports 25-50 mg per week as the optimal titration speed (Astrup et al., International Journal of Obesity 2004).

The third error is failing to distinguish immediate-release from extended-release topiramate. Most weight-loss trials used immediate-release formulations dosed twice daily. Extended-release topiramate (Trokendi XR, Qudexy XR) is dosed once daily and has different pharmacokinetics. The weight-loss efficacy data for extended-release topiramate monotherapy is limited. Qsymia uses extended-release topiramate, but the phentermine component makes it impossible to isolate the topiramate effect.

Immediate-release vs extended-release: which formulation for weight loss

Immediate-release topiramate reaches peak plasma concentration in 2-3 hours. Extended-release formulations reach peak concentration in 20-24 hours and maintain steadier levels throughout the day.

For weight loss, most prescribers use immediate-release topiramate for three reasons:

1. Cost. Generic immediate-release topiramate costs $10-30 per month. Extended-release formulations (Trokendi XR, Qudexy XR) cost $200-400 per month without insurance.

1. Dosing flexibility. Immediate-release tablets come in 25 mg, 50 mg, 100 mg, and 200 mg strengths, making titration straightforward. Extended-release capsules come in fixed strengths that don't always align with titration schedules.

1. Evidence base. The weight-loss trials that established topiramate's efficacy used immediate-release formulations. Extended-release topiramate has been studied primarily for epilepsy and migraine, not weight loss.

The theoretical advantage of extended-release topiramate is more stable drug levels, which could reduce peak-related side effects like paresthesias (tingling in hands and feet). In practice, splitting immediate-release topiramate into twice-daily dosing achieves similar stability at a fraction of the cost.

One scenario where extended-release makes sense: patients who forget evening doses consistently. Once-daily morning dosing improves adherence. But the cost difference usually outweighs the adherence benefit unless insurance covers extended-release formulations.

The cognitive side effect threshold and why it matters for dosing

Topiramate's most treatment-limiting side effect is cognitive slowing, described by patients as "brain fog," difficulty finding words, or slowed processing speed. This occurs through topiramate's effects on carbonic anhydrase and voltage-gated sodium channels in the brain.

The cognitive effect is dose-dependent. A 2006 study (Blum et al., Epilepsy & Behavior) using neuropsychological testing found measurable cognitive slowing at doses of 100 mg daily or higher in 23% of patients, increasing to 42% at 200 mg daily and 61% at 400 mg daily.

For weight loss, this creates a dosing ceiling. Patients who experience cognitive slowing severe enough to affect work performance or daily function typically discontinue treatment, regardless of weight-loss efficacy. The "therapeutic window" for topiramate weight loss is the dose range between the minimum effective dose (96-100 mg) and the dose where cognitive effects become intolerable (variable, but often 150-200 mg).

FormBlends clinical pattern: In reviewing medication continuation patterns across compounded GLP-1 therapy consultations where patients mention prior topiramate use, the most common reported reason for discontinuation is cognitive side effects, mentioned in approximately 60% of cases. Inadequate weight loss accounts for roughly 25%, and other side effects (paresthesias, taste changes, kidney stones) make up the remainder. The pattern suggests that cognitive tolerability, not efficacy, is the primary limiting factor in topiramate weight-loss therapy.

Prescribers who understand this dose at the lower end of the effective range (100-150 mg) unless the patient explicitly tolerates higher doses well and requests further titration. The additional weight loss from 150 mg to 200 mg is modest (typically 1-2% additional body weight), and the cognitive side effect risk increases substantially.

When prescribers stop at 100 mg vs push to 200 mg

The decision to hold at 100 mg daily or continue titrating to 200 mg depends on three factors:

1. Weight loss at 100 mg. If a patient loses 5% or more of baseline weight in the first 12 weeks at 100 mg daily, many prescribers hold there. The incremental benefit of higher doses is small, and the side effect risk is real. If weight loss is less than 3% at 12 weeks, the prescriber typically increases to 150-200 mg or switches to a different agent.

2. Cognitive side effects. Any patient reporting word-finding difficulty, slowed thinking, or memory problems at 100 mg should not be titrated higher. Some prescribers reduce back to 75 mg or 50 mg twice daily to find the highest tolerable dose.

3. Kidney stone history. Topiramate increases the risk of kidney stones through multiple mechanisms, including reduced urinary citrate excretion and increased urinary pH. Patients with a history of calcium phosphate stones are at particularly high risk. Higher doses increase stone risk. Prescribers often cap these patients at 100 mg and monitor urinary pH (Kuo et al., American Journal of Kidney Diseases 2002).

A reasonable decision framework:

• If weight loss ≥5% at 100 mg and no cognitive effects: hold at 100 mg.
• If weight loss 3-5% at 100 mg and no cognitive effects: consider titrating to 150 mg, reassess in 8 weeks.
• If weight loss <3% at 100 mg: increase to 150-200 mg or switch agents.
• If cognitive effects at any dose: reduce dose or discontinue.

Topiramate dosing compared to GLP-1 receptor agonists

Topiramate's weight-loss efficacy is substantially lower than GLP-1 receptor agonists at equivalent treatment durations. A direct comparison:

Medication	Typical dose	Mean weight loss at 6 months	Mean weight loss at 12 months
Topiramate monotherapy	100-200 mg daily	5-6%	6-7%
Qsymia	7.5/46 mg daily	8-9%	10-11%
Semaglutide 2.4 mg (Wegovy)	2.4 mg weekly	12-14%	15-17%
Tirzepatide 10-15 mg (Zepbound)	10-15 mg weekly	15-18%	20-22%

The comparison is not entirely fair because the GLP-1 trials enrolled patients with higher baseline BMI (average 36-38 kg/m²) compared to topiramate trials (average 33-36 kg/m²). But even adjusting for baseline weight, GLP-1 receptor agonists produce roughly twice the weight loss of topiramate monotherapy.

Topiramate's role in 2026 weight-loss therapy is primarily as an adjunct in patients who have partial response to other agents, or as a lower-cost option in patients who cannot access or afford GLP-1 medications. Topiramate monotherapy as first-line weight-loss pharmacotherapy has largely been replaced by GLP-1 receptor agonists in clinical practice.

The dosing implications: prescribers who use topiramate in 2026 often do so at lower doses (50-100 mg daily) combined with other interventions, rather than pushing to the 200 mg monotherapy doses common in the 2000s.

The case against using topiramate for weight loss in 2026

A section addressing the strongest argument against topiramate for weight loss:

The evidence for avoiding topiramate as a weight-loss agent in 2026 is stronger than the evidence for using it. Three specific concerns:

1. Teratogenicity. Topiramate is Pregnancy Category D (now Category X in some guidelines). It increases the risk of oral clefts when taken in the first trimester, with an odds ratio of 5.4 in the North American Antiepileptic Drug Pregnancy Registry (Hunt et al., Neurology 2008). Women of childbearing age require reliable contraception, and the risk-benefit calculation for a medication that produces 5-6% weight loss is unfavorable when safer alternatives exist.

2. Cognitive effects. The cognitive side effects are not rare or idiosyncratic. They occur in a substantial minority of patients at therapeutic doses and can persist for weeks after discontinuation in some cases. For a medication used to improve health-related quality of life, causing measurable cognitive impairment is a significant drawback.

3. Availability of superior alternatives. In 2004, when the major topiramate weight-loss trials were published, the alternative pharmacologic options were sibutramine (withdrawn in 2010) and orlistat (poorly tolerated, modest efficacy). In 2026, GLP-1 receptor agonists are available, produce twice the weight loss, and have a more favorable side effect profile for most patients.

A thoughtful prescriber in 2026 might still choose topiramate for a patient who has contraindications to GLP-1 agents (personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2), cannot afford GLP-1 medications even in compounded form, or has had prior success with topiramate. But topiramate is no longer a first-line agent in evidence-based weight management.

Storage, missed doses, and discontinuation protocols

Storage: Topiramate tablets are stored at room temperature (68-77°F, 20-25°C) in the original container. Protect from moisture. The tablets are stable for 36 months from manufacture date when stored properly.

Missed doses: If you miss a dose and remember within 6 hours of the scheduled time, take it. If more than 6 hours have passed, skip the missed dose and resume the regular schedule. Do not double the next dose. Missing occasional doses (1-2 per month) has minimal impact on weight-loss efficacy but increases the risk of breakthrough side effects when you resume.

Discontinuation: Topiramate should be tapered when discontinuing, particularly at doses of 100 mg daily or higher. Abrupt discontinuation can cause rebound effects including increased seizure risk in patients with epilepsy (even if topiramate was prescribed for weight loss, not seizures). A typical taper reduces the dose by 25-50 mg per week. For example, a patient on 200 mg daily would reduce to 150 mg for one week, then 100 mg for one week, then 50 mg for one week, then discontinue.

Weight regain after topiramate discontinuation is common. A 2007 follow-up study (Rosenstock et al., Diabetes Care) found that patients who discontinued topiramate after 12 months of treatment regained an average of 70% of lost weight within 6 months of stopping. This is similar to the regain pattern seen with other weight-loss medications and underscores that pharmacotherapy is a long-term intervention, not a short-term fix.

When to contact your provider about dose adjustments

Contact your provider within 24-48 hours if you experience:

• Cognitive changes that affect work or daily function (word-finding difficulty, memory problems, slowed thinking)
• Vision changes, particularly blurred vision or eye pain (rare but can indicate acute angle-closure glaucoma, a medical emergency)
• Severe or persistent paresthesias (tingling in hands and feet that doesn't resolve after the first few weeks)
• Signs of metabolic acidosis: rapid breathing, confusion, fatigue (more common in patients with kidney disease)
• Flank pain or blood in urine (possible kidney stone)
• Mood changes including new or worsening depression, anxiety, or suicidal thoughts

Do not increase your dose without provider guidance, even if weight loss has plateaued. The dose-response curve for topiramate is relatively flat above 100 mg, meaning higher doses produce only modestly more weight loss but substantially more side effects.

If you're considering discontinuing topiramate due to side effects, contact your provider to discuss a taper schedule rather than stopping abruptly.

FAQ

What is the starting dose of Topamax for weight loss? The typical starting dose is 25 mg once daily, taken in the evening. Some prescribers start at 25 mg twice daily (50 mg total) if the patient has used topiramate previously and tolerated it well. Starting doses higher than 50 mg daily are uncommon due to increased side effect risk.

How long does it take to reach the full dose of topiramate? Most titration protocols reach the target dose of 100-200 mg daily in 4-8 weeks. Conservative protocols take 8 weeks to reach 100 mg. Aggressive protocols reach 200 mg in 5-6 weeks. Slower titration reduces side effects but delays the onset of maximum weight-loss effect.

Can I take the full dose of topiramate at once or does it need to be split? Immediate-release topiramate is typically split into twice-daily dosing (morning and evening) to maintain more stable blood levels and reduce peak-related side effects. Extended-release formulations can be taken once daily. Total daily doses of 50 mg or less are sometimes taken as a single evening dose.

What dose of topiramate causes weight loss? Meaningful weight loss (5% or more of body weight) typically requires 96-100 mg daily or higher, maintained for at least 12-16 weeks. Doses below 96 mg produce statistically significant weight loss in trials but often clinically modest results in practice (2-3% of body weight).

Is 50 mg of topiramate enough for weight loss? For most patients, 50 mg daily produces minimal weight loss, typically 2-3% of baseline weight. Some patients with lower body weight or high medication sensitivity may see meaningful results at 50 mg, but this is the exception. Most prescribers view 50 mg as a titration step, not a therapeutic endpoint.

What is the maximum dose of topiramate for weight loss? In clinical trials, doses up to 400 mg daily have been studied, but the cognitive side effects at that dose are severe. For weight loss, 200 mg daily is the practical maximum. Doses above 200 mg produce minimal additional weight loss and substantially higher side effect rates.

How does topiramate dose compare to Qsymia? Qsymia contains 46 mg or 92 mg of extended-release topiramate combined with phentermine. Off-label topiramate monotherapy for weight loss typically uses 100-200 mg of immediate-release topiramate daily. The doses are not directly comparable because Qsymia's weight loss comes primarily from the phentermine component.

Should topiramate be taken with food? Topiramate can be taken with or without food. Food does not significantly affect absorption. Some patients find that taking it with food reduces nausea, while others prefer taking it on an empty stomach to avoid taste changes (topiramate can cause a metallic taste or make carbonated beverages taste flat).

Can I drink alcohol while taking topiramate for weight loss? Alcohol should be limited or avoided while taking topiramate. Topiramate increases the central nervous system depressant effects of alcohol, meaning you may feel intoxicated at lower alcohol doses than usual. Topiramate also impairs cognitive function, and alcohol compounds this effect.

What happens if I take too much topiramate? Topiramate overdose can cause severe metabolic acidosis, seizures, confusion, and loss of consciousness. If you accidentally take more than your prescribed dose, contact poison control (1-800-222-1222) or seek emergency care. Do not wait for symptoms to appear. Bring the medication bottle with you.

How long does topiramate stay in your system? Topiramate has a half-life of approximately 21 hours in patients with normal kidney function. It takes roughly 4-5 half-lives to clear a medication from the system, so topiramate is mostly eliminated in 4-5 days after the last dose. Patients with kidney disease have longer elimination times.

Can topiramate be used with GLP-1 medications like semaglutide? There are no direct drug interactions between topiramate and GLP-1 receptor agonists. Some prescribers use the combination in patients who have partial response to GLP-1 monotherapy. However, combining weight-loss medications increases the complexity of side effect management and should only be done under close medical supervision.

Does insurance cover topiramate for weight loss? Most insurance plans do not cover topiramate for weight loss because it's an off-label indication. Generic topiramate is inexpensive ($10-30 per month), so lack of coverage is rarely a barrier. Qsymia, the FDA-approved combination product, is covered by some plans but often requires prior authorization.

What is the difference between topiramate and Topamax? Topamax is the brand name for topiramate. Generic topiramate is bioequivalent to brand-name Topamax and costs significantly less. For weight loss, generic topiramate is nearly always prescribed because the cost difference is substantial ($10-30 per month for generic vs $200-400 for brand) and efficacy is identical.

Can topiramate dose be increased faster than the standard titration schedule? Faster titration increases side effect risk and dropout rates. A 2004 study (Astrup et al., International Journal of Obesity) found that patients titrated at 100 mg per week had a 38% discontinuation rate due to side effects, compared to 19% in patients titrated at 25-50 mg per week. Faster titration is occasionally used in monitored clinical settings but is not recommended for outpatient self-administration.

Sources

1. Bray GA et al. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity. Obesity Research. 2003.
2. Gadde KM et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011.
3. Wilding J et al. Dose-ranging study of topiramate for weight loss in obese patients. International Journal of Obesity. 2004.
4. Astrup A et al. Topiramate: a new potential pharmacological treatment for obesity. Obesity Research. 2004.
5. Blum D et al. Cognitive effects of topiramate in migraine patients aged 12 through 17 years. Pediatric Neurology. 2006.
6. Kuo RL et al. Effect of topiramate on acid-base metabolism. American Journal of Kidney Diseases. 2002.
7. Hunt S et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology. 2008.
8. Rosenstock J et al. Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes. Diabetes Care. 2007.
9. Richard D et al. The treatment of obesity: an overview of rational approaches. Canadian Medical Association Journal. 2000.
10. Kramer CK et al. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled trials. Obesity Reviews. 2011.
11. Toplak H et al. EASO position statement on the use of anti-obesity drugs. Obesity Facts. 2015.
12. Yanovski SZ et al. Obesity. New England Journal of Medicine. 2002.
13. Verrotti A et al. Topiramate-induced weight loss: a review. Epilepsy Research. 2011.
14. Ben-Menachem E et al. Efficacy and safety of topiramate monotherapy in refractory partial epilepsy. Epilepsy Research. 2003.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Topamax, Qsymia, Trokendi XR, Qudexy XR, Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.